专注于肿瘤浸润淋巴细胞（TIL）技术的突破性发展，坚持以高标准建设科研创新平台，汇聚国内外高层次人才，是一支具有国际先进水平的高端生物开发、产业化人才团队。

Pioneers breakthrough advancements in Tumor-Infiltrating Lymphocyte (TIL) technology.assembling world-class scientific talentto forman elite team with internationally recognized expertise in biotherapeutic development and industrialization.

品牌创始人情况简介

Introduction to the founder of the brand

刘翔/博士

Dr.Liu Xiang

复旦大学生物医药博士

首席执行官/技术官

厦门泰生源细胞科技研究院院长

湖南文理学院产业教授

专注肿瘤和阿尔茨海默病创新药物研发；

拥有14年新药申报经验（上海医药工业研究院/中国医药工业研究总院），已发表研究论文16篇，申请专利4项；

曾参与多项化药和3项细胞药物IND申报，在TIL工艺开发和临床研究方面具有丰富的经验，负责TIL细胞治疗的研发以及IND推进，以及肿瘤组织存储生物库的建设和运营。

Focused on pioneering therapeutics for oncology and Alzheimer’s disease, leveraging 14 years of drug registration expertise (Shanghai Institute of Pharmaceutical Industry/China State Institute of Pharmaceutical Industry) with 16 peer-reviewed publications and 4 patent applications.

Key experience includes:

-Participation in multiple chemical drug IND submissions and 3 cell-based therapy IND programs.

-Extensive background in TIL process development and clinical research.

-Leadership in TIL therapy R&D and IND advancement.

-Establishment and management of tissue-derived immune cell biobanking systems.